Literature DB >> 1706671

Co-expression of X-hapten-like antigen and antigen YH206 on mucin molecules.

Y Hinoda1, K Imai, T Ban, F Itoh, A Yachi.   

Abstract

The asialocarbohydrate antigen YH206 is expressed on adenocarcinoma-associated mucin molecules which lack epitopes of CA19-9 and DU-PAN-2. To further characterize this molecule, the monoclonal antibody BM2 against the affinity-purified antigen YH206 was established. It was demonstrated by an inhibition test that antigen BM2 was an X-hapten-like structure, one of the representative oncodevelopmental antigens. Although the sensitivity of antigen BM2 in sera of stomach and pancreas cancer patients did not appear to be superior to that of antigen YH206, both antigens were complementary to each other resulting in the improvement of sensitivity. Interestingly, double-determinant enzyme immunoassays showed that antigen BM2 and YH206, both having a cryptic nature for neuraminidase, were co-expressed on the same mucin molecule in sera of patients with stomach cancer or liver cirrhosis. These data suggest that mucin molecules in serum might be classified into several groups based on the distribution of tumor-associated epitopes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706671     DOI: 10.1007/bf02779510

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  19 in total

1.  Immunohistochemical analysis of human adenocarcinoma-associated antigen YH206 detected by a monoclonal antibody.

Authors:  A Yachi; K Imai; T Endo; Y Hinoda
Journal:  Jpn J Med       Date:  1986-05

2.  Lex and Ley antigen expression in human pancreatic cancer.

Authors:  Y S Kim; S H Itzkowitz; M Yuan; Y Chung; K Satake; K Umeyama; S Hakomori
Journal:  Cancer Res       Date:  1988-01-15       Impact factor: 12.701

3.  A sandwich enzyme immunoassay of an adenocarcinoma-associated antigen, YH206, in cancer sera.

Authors:  Y Hinoda; K Imai; T Ban; T Endo; A Yachi
Journal:  Jpn J Cancer Res       Date:  1987-06

4.  Application of monoclonal antibody KH2 against lactosyl and neolactotetraosyl ceramide to immunohistochemical study of human cancers.

Authors:  Y Hinoda; K Imai; F Itoh; N Nakagawa; M Naiki; A Yachi
Journal:  Tumour Biol       Date:  1989

5.  Location and distribution of difucoganglioside (VI3NeuAcV3III3Fuc2nLc6) in normal and tumor tissues defined by its monoclonal antibody FH6.

Authors:  Y Fukushi; R Kannagi; S Hakomori; T Shepard; B G Kulander; J W Singer
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

6.  Immunochemical characterization of adenocarcinoma-associated antigen YH206.

Authors:  Y Hinoda; K Imai; T Ban; T Endo; A Yachi
Journal:  Int J Cancer       Date:  1988-11-15       Impact factor: 7.396

7.  Carbohydrate determinants associated with carcinoembryonic antigen (CEA).

Authors:  E J Nichols; R Kannagi; S I Hakomori; M J Krantz; A Fuks
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

8.  Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.

Authors:  H Takasaki; E Uchida; M A Tempero; D A Burnett; R S Metzgar; P M Pour
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701

9.  Measurement of a pancreatic cancer-associated antigen (DU-PAN-2) detected by a monoclonal antibody in sera of patients with digestive cancers.

Authors:  N Sawabu; D Toya; Y Takemori; N Hattori; M Fukui
Journal:  Int J Cancer       Date:  1986-05-15       Impact factor: 7.396

10.  Novel fucolipids accumulating in human adenocarcinoma. II. Selective isolation of hybridoma antibodies that differentially recognize mono-, di-, and trifucosylated type 2 chain.

Authors:  Y Fukushi; S Hakomori; E Nudelman; N Cochran
Journal:  J Biol Chem       Date:  1984-04-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.